Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Papers
(The TQCC of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Rapid classification of a novel ALS-causing I149S variant in superoxide dismutase-147
Low plasma hyaluronan is associated with faster functional decline in patients with amyotrophic lateral sclerosis36
Clinical and demographical characteristics in a cohort of MND patients treated with riluzole. Differences between tablets and oral suspension32
Correction26
The correlation between social support, coping style, advance care planning readiness, and quality of life in patients with amyotrophic lateral sclerosis: a cross-sectional study25
Incorporating patient preferences and burden-of-disease in evaluating ALS drug candidate AMX0035: a Bayesian decision analysis perspective24
The amyotrophic lateral sclerosis-health index (ALS-HI): development and evaluation of a novel outcome measure20
Validity and reliability measures of the Swedish Karolinska version of the Edinburgh Cognitive and Behavioral ALS Screen (SK-ECAS)19
Single task-level, 2SD-based cutoffs for the Italian version of the Edinburgh Cognitive and Behavioral ALS screen (ECAS)19
Clinical epidemiology of amyotrophic lateral sclerosis in Liguria, Italy: a ten year follow up study19
Geographical clusters of amyotrophic lateral sclerosis and the Bradford Hill criteria18
Genetic ancestry and risk allele C9orf72 rs3849942 T for amyotrophic lateral sclerosis in Latin American populations18
Development, reliability, validity, and acceptability of the remote administration of the Edinburgh Cognitive and Behavioural ALS Screen (ECAS)18
Patient engagement in research: lessons learned from CAPTURE ALS, a longitudinal observational ALS study15
Peripheral immunity relate to disease progression and prognosis in amyotrophic lateral sclerosis15
Incidence of amyotrophic lateral sclerosis before and during the COVID-19 pandemic: evidence from an 8-year population-based study in Central Italy based on healthcare utilization databases15
Theme 5 Human Cell Biology and Pathology15
Residential exposure associations with ALS risk, survival, and phenotype: a Michigan-based case-control study15
Amyotrophic lateral sclerosis mortality rates in Latin America and the Caribbean: a meta-analysis14
Assessing pulmonary function in ALS using electrical impedance tomography14
Epidemiology, clinical features, and management of amyotrophic lateral sclerosis in the neurology department of the Bogodogo University Hospital in Ouagadougou, Burkina Faso14
Can resting lung function predict the response of a person living with motor neuron disease to a hypoxic challenge test?14
Impact of occupational categories on the incidence of amyotrophic lateral sclerosis in Sardinia Island, Italy14
Theme 11 - Cognitive and Psychological Assessment and Support14
Genetic variation in targets of lipid-lowering drugs and amyotrophic lateral sclerosis risk: a Mendelian randomization study13
Theme 10 - Disease Stratification and Phenotyping of Patients13
Portable fixed dynamometry enables home-based, reliable assessment of muscle strength in patients with amyotrophic lateral sclerosis: a pilot study13
Time from amyotrophic lateral sclerosis symptom onset to key disease milestones: analysis of data from a multinational cross-sectional survey12
Care burden and related factors among informal caregivers of patients with amyotrophic lateral sclerosis12
Theme 03 - IN VITRO EXPERIMENTAL MODELS11
Amyotrophic lateral sclerosis: exploring pathophysiology in the context of treatment11
Yield of EEG features as markers of disease severity in amyotrophic lateral sclerosis: a pilot study11
Correction11
Self-assessment of amyotrophic lateral sclerosis functional rating scale on the patient’s smartphone proves to be non-inferior to clinic data capture11
Supporting people with Motor Neuron Disease (MND) to make decisions about gastrostomy feeding tube placement: a survey of UK healthcare professionals’ practice and beliefs10
The involvement of palliative care with neurology – a comparison of UK, Switzerland and Italy10
Slowly progressive late-onset spinal muscular atrophy Finkel-type related to p.Pro56Ser VABP mutation in Colombia10
Automated speech analytics in ALS: higher sensitivity of digital articulatory precision over the ALSFRS-R10
Feature selection using metaheuristics to predict annual amyotrophic lateral sclerosis progression10
Drug treatments and interactions, disease progression and quality of life in ALS patients9
Platform Communications: Abstract Book – 33rd International Symposium on ALS/MND (Complete printable file)9
The contralateral co-movement test in a Chinese population with amyotrophic lateral sclerosis9
Expanding the phenotype of TARDBP mutation in a Tunisian family with clinical phenotype heterogeneity9
Time-to-event prediction in ALS using a landmark modeling approach, using the ALS Natural History Consortium dataset9
Improving the measurement properties of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R): deriving a valid measurement total for the calculation of change9
Exposure to electromagnetic fields does not modify neither the age of onset nor the disease progression in ALS patients9
International network for ALS research and care (INARC)9
A novel TBK1 loss-of-function variant associated with ALS and parkinsonism phenotypes9
Toward genetic counseling practice standards for diagnostic testing in amyotrophic lateral sclerosis and frontotemporal dementia9
Neuropsychological assessment practices in PRECISION-ALS: challenges and opportunities for harmonization9
Amyotrophic lateral sclerosis estimated prevalence cases from 2022 to 2030, data from the national ALS Registry9
A revision to the United States national ALS registry’s algorithm to improve Case-Ascertainment8
The association of theory of mind with language and visuospatial abilities in amyotrophic lateral sclerosis: a pilot study8
Response letter to: a homozygous p.Val120Leu (c.358G > C) SOD1 mutation led to slowly progressive amyotrophic lateral sclerosis in a Brazilian family8
IMPACT-ALS: summary of results from a European survey of people living with ALS8
PRECISION ALS—an integrated pan European patient data platform for ALS8
The natural history of ALS: Baseline characteristics from a multicenter clinical cohort8
Comparison Of King’s Clinical Staging In Multinational Amyotrophic Lateral Sclerosis Cohorts8
Exploring the needs and preferences of people with amyotrophic lateral sclerosis (ALS) when making genomic testing decisions: an interview study7
Epidemiology and economic burden of amyotrophic lateral sclerosis in the United States: a literature review7
Respiratory measurements, respiratory symptoms, and quality of life in ALS: results from the REVEALS study7
Body mass index is lower in asymptomatic C9orf72 expansion carriers but not in SOD1 pathogenic variant carriers compared to gene negatives7
Cognition in the course of ALS—a meta-analysis7
Changes in saccadic intrusions over time as an objective biomarker to follow ALS disease progression7
Increased total daily energy expenditure in mild to moderate ALS: greater contribution from physical activity energy expenditure than hyper-metabolism7
Impact of mode of training and recertification on ALSFRS-R rater performance6
Theme 03 - In Vitro Experimental Models6
Primary lateral sclerosis natural history study – planning, designing, and early enrollment6
Theme 05 - HUMAN CELL BIOLOGY AND PATHOLOGY (including iPSC studies)6
Quantitative susceptibility mapping for investigating brain iron deposits in amyotrophic lateral sclerosis: correlations with clinical phenotype and disease progression6
Theme 12 - Clinical Management and Support6
Neurofilament light chain as a biological marker for amyotrophic lateral sclerosis: a meta-analysis study6
The cholesterol depleting agent, (2-Hydroxypropyl)-ß-cyclodextrin, does not affect disease progression in SOD1 G93A mice6
Urine specific gravity to identify and predict hydration need in ALS6
ALSUntangled #79: alpha-lipoic acid6
A speech-based prognostic model for dysarthria progression in ALS6
MiNDAUS partnership: a roadmap for the cure and management of motor Neurone disease6
Why is nutrition vital for advancing ALS care and clinical research?6
ALSUntangled #80: ISRIB (Integrated stress response InhiBitor)6
ALSUntangled # 69: astaxanthin6
The diagnostic value of the Italian version of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS)6
How the prospect of a clinical trial impacts decision-making for predictive genetic testing in ALS6
Apathy in amyotrophic lateral sclerosis: systematic review and meta-analysis of frequency, correlates, and outcomes6
Demographic changes in a large motor neuron disease cohort in Portugal: a 27 year experience6
Association of UNC13A with increased amyotrophic lateral sclerosis risk, bulbar onset, and lower motor neuron involvement in a Norwegian ALS cohort5
Serum heat shock protein concentrations are not associated with amyotrophic lateral sclerosis risk or survival in three European populations5
The Beaumont behavioral intervention in a Chinese amyotrophic lateral sclerosis cohort5
Theme 10 - DISEASE STRATIFICATION AND PHENOTYPING OF PATIENTS5
A verb-naming test accurately detects cognitive changes in ALS5
Letter to Editor5
ALSUntangled #65: glucocorticoid corticosteroids5
Theme 08 - Clinical Imaging and Electrophysiology5
Study of “ALS reversals”: LifeTime environmental exposures (StARLiTE)5
Longitudinal comparison of the self-administered ALSFRS-RSE and ALSFRS-R as functional outcome measures in ALS5
A de novo c.113 T > C: p.L38R mutation of SPTLC1: case report of a girl with sporadic juvenile amyotrophic lateral sclerosis5
Correction5
Acceptability and potential benefit of a self-compassion intervention for people living with amyotrophic lateral sclerosis: a mixed methods pilot study5
Neutrophil-to-lymphocyte ratio at diagnosis as a biomarker for survival of amyotrophic lateral sclerosis4
Harmonized standard operating procedures for administering the ALS functional rating scale-revised4
Characterization, epidemiology, and factors associated with evolution and survival in patients with amyotrophic lateral sclerosis in southeastern Spain, 2008–2021: a population-based study4
Verbal expressive language minimally affected in non-demented people living with amyotrophic lateral sclerosis4
The expanding clinical and genetic spectrum of alsin-related disorders: the first cohort of Brazilian patients4
Prevalence of depression in amyotrophic lateral sclerosis/motor neuron disease: multi-attribute ascertainment and trajectories over 30 months4
Occupational lead exposure and amyotrophic lateral sclerosis survival in the Danish National Patient Registry4
Mapping the natural history of amyotrophic lateral sclerosis: time-to-event analysis of clinical milestones in the pan-European, population-based PRECISION-ALS cohort4
Thoracic electrical impedance tomography for assessing progression of pulmonary dysfunction in ALS4
HLA and amyotrophic lateral sclerosis: a systematic review and meta-analysis4
Frequency of C9orf72 and SOD1 mutations in 302 sporadic ALS patients from three German ALS centers4
Theme 01 - Epidemiology and Informatics4
Patients’ choices regarding ventilatory support affect opioid use in amyotrophic lateral sclerosis4
Theme 02 - Genetics and Genomics4
In memoriam Ettore Beghi, 1947–20224
Effects of COVID-19 on motor neuron disease mortality in the United States: a population-based cross-sectional study4
Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial4
Incidence of amyotrophic lateral sclerosis in the United States, 2014–20164
Theme 05 - Human Cell Biology and Pathology (including iPSC studies)4
ALSUntangled #71: Nuedexta4
Current practices in the nutrition management of people with amyotrophic lateral sclerosis (ALS): a survey of U.S. ALS care teams4
0.084500074386597